COVID-19 Vaccine for symptomatic patients

Phase 1/2 Data

Exp Date

Q1 2021

Amp Volatility Score

Catalyst Info & Data Links



  • By utilizing the Company’s proprietary intranasal vaccine technology, it is expected that AdCOVID has the potential to activate multiple arms of the immune system as shown in a recent Phase 2 clinical study with NasoVAX, an influenza vaccine candidate based on the same platform technology

  • (Source)

Updated by HC


Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

Small Cap COVID-19 Vaccine Pla...

Based on our research and analysis, some interesting small cap COVID-19 Vaccine players that are traded on U.S. markets are ARCT, INO, ALT and VXRT. These four appear to have clinical trial data reado...

ALT - Announce Potent Respirat...

The latest study showed potent stimulation of antigen-specific CD4+ and CD8+ T cells in the lungs of CD-1 mice as early as 10 days following a single intranasal vaccination, with responses strongly bi...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon